Related Experiment Video
Updated: Jul 21, 2025
04:12
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
Published on: January 19, 2024
953
Topical Tranexamic Acid Does Not Reduce Hematoma in Reduction Mammaplasty: A Double-Blind Randomized Controlled Trial
Amy Yao1, Fei Wang1, Teresa Benacquista1
1From the Division of Plastic Surgery, Montefiore Medical Center.
Plastic and Reconstructive Surgery
|July 28, 2023
Summary
Topical tranexamic acid (TXA) did not reduce hematoma rates in breast reduction surgery. This study found no significant difference in complications when TXA was applied topically during mammaplasty procedures.
Area of Science:
- Plastic Surgery
- Surgical Hemorrhage Control
Background:
- Breast reduction mammaplasty is a common plastic surgery procedure.
- Postoperative hematoma occurs in 1% to 7% of cases.
- Tranexamic acid (TXA) is known to reduce bleeding but is underutilized in plastic surgery.
Purpose of the Study:
- To evaluate the efficacy of topical tranexamic acid (TXA) in reducing postoperative hematoma after breast reduction mammaplasty.
Main Methods:
- A double-blind, randomized controlled trial involving 98 patients undergoing bilateral reduction mammaplasty.
- One breast received 1000 mg of topical TXA before closure; the other received saline as a control.
- Postoperative complications, including hematoma, drain output, and drain duration, were compared.
Main Results:
- The overall hematoma rate was 1.5%.
- Topical TXA application showed no significant association with reduced hematoma incidence (P=0.56).
- TXA did not significantly impact drain output or lead to adverse events.
Conclusions:
- Topical tranexamic acid (TXA) does not decrease the incidence of hematoma following reduction mammaplasty.
- Further research may explore alternative TXA administration methods or patient populations.
